β-lactam/β-lactamase inhibitor combinations (AAC ed.)

<p>The development of β-lactam/β-lactamase inhibitors seems to be expanding rapidly and promise to be the best short-term strategy against the most recalcitrant Gram-negative pathogens. In this podcast, we will discuss the current state of the art in this field.<br /> <br /> Objectives:</p> <p>• Discuss how the discovery of β-lactam/β-lactam inhibitors has evolved<br /> • Review the current state-of-the-art of developing of novel β-lactam/β-lactamase inhibitors</p> <p>• Analyze the current and future clinical applications of these drugs against major antimicrobial-resistant pathogens.</p> <p><strong>Guests:</strong></p> <ul> <li>Robert Bonomo, MD. Professor and Associate Chief of Staff for Academic Affairs; Director Case-VA Center for Antimicrobial Resistance and Epidemiology, Case Western Research University, School of Medicine. Past Editor of AAC</li> <li>Pranita Tamma, MD. MH.S. Associate Professor of Pediatrics and Director, Pediatric Antimicrobial Stewardship Program. Johns Hopkins University. Editor of AAC.</li> </ul> <p><br /> Visit <a href="https://aac.asm.org">https://aac.asm.org</a> to read more</p>